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The intra vitam diagnosis of prion disease is challenging and a deﬁnite diagnosis still requires neuropathological examination in
non-familial cases. Magnetic resonance imaging has gained increasing importance in the diagnosis of prion disease. The aim of
this study was to compare the usefulness of different magnetic resonance imaging sequences and proton magnetic resonance
spectroscopy in the differential diagnosis of patients with rapidly progressive neurological signs compatible with the clinical
diagnosis of sporadic prion disease. Twenty-nine consecutive patients with an initial diagnosis of possible or probable sporadic
prion disease, on the basis of clinical and electroencephalography features, were recruited. The magnetic resonance protocol
included axial ﬂuid-attenuated inversion recovery-T2- and diffusion-weighted images, and proton magnetic resonance spectro-
scopy of the thalamus, striatum, cerebellum and occipital cortex. Based on the clinical follow-up, genetic studies and neuro-
pathology, the ﬁnal diagnosis was of prion disease in 14 patients out of 29. The percentage of correctly diagnosed cases was
86% for diffusion-weighted imaging (hyperintensity in the striatum/cerebral cortex), 86% for thalamic N-acetyl-aspartate to
creatine ratio (cutoff 41.21), 90% for thalamic N-acetyl-aspartate to myo-inositol (mI) ratio (cutoff 41.05) and 86% for
cerebral spinal ﬂuid 14-3-3 protein. All the prion disease patients had N-acetyl-aspartate to creatine ratios 41.21 (100%
sensitivity and 100% negative predictive value) and all the non-prion patients had N-acetyl-aspartate to myo-inositol ratios
41.05 (100% speciﬁcity and 100% positive predictive value). Univariate logistic regression analysis showed that the combi-
nation of thalamic N-acetyl-aspartate to creatine ratio and diffusion-weighted imaging correctly classiﬁed 93% of the patients.
The combination of thalamic proton magnetic resonance spectroscopy (10min acquisition duration) and brain diffusion-
weighted imaging (2min acquisition duration) may increase the diagnostic accuracy of the magnetic resonance scan. Both
sequences should be routinely included in the clinical work-up of patients with suspected prion disease.
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Introduction
Prion diseases are rare, fatal, neurodegenerative disorders mainly
affecting the central nervous system, which can be familial,
sporadic or acquired by infection (Gambetti et al., 2003).
The intra vitam diagnosis is challenging as there is currently no
non-invasive in vivo diagnostic test and a deﬁnite diagnosis still
requires neuropathological examination in non-familial cases. The
initial diagnostic suspicion of prion disease is clinical and usually
raised in the presence of rapidly progressive neurological signs not
associated with focal neuroradiological abnormalities. Two para-
clinical tests are currently used to increase the clinical diagnostic
sensitivity and speciﬁcity: electroencephalography (EEG) recording
and testing the cerebrospinal ﬂuid (CSF) for 14-3-3 protein
(Zerr et al., 2000). Patients with Creutzfeldt–Jakob disease
(CJD), the most common human prion disease, may show periodic
sharp and slow wave complexes in the EEG and, at a higher rate,
increased CSF levels of the 14-3-3 protein. Sensitivity and speciﬁ-
city of periodic sharp and slow wave complexes (66 and 74%,
respectively) are lower compared with the 14-3-3 analysis, which
showed an overall sensitivity of 94% and speciﬁcity of 84% (Zerr
et al., 2000; Steinhoff et al., 2004). On the other hand, when the
14-3-3 test was used on unselected patients with dementia, half
of them rapidly progressive (disease duration 412 months), a rate
of 12% false positive cases was revealed (Burkhard et al., 2001).
Furthermore, fatal insomnia, a rare atypical form of sporadic prion
disease, lacks increased CSF levels of the 14-3-3 protein in nearly
all cases (Krasnianski et al., 2008).
Magnetic resonance imaging (MRI) has gained increasing
importance in the diagnosis of prion diseases (Collie et al., 2001;
Tschampa et al., 2007). A symmetric hyperintense signal in the
caudate nucleus and putamen is regarded as typical, particularly
on ﬂuid-attenuated inversion recovery (FLAIR) and diffusion-
weighted images (DWI) (Bahn and Parchi 1999; Schro ¨ter et al.,
2000; Shiga et al., 2004). In the largest MRI study available, 193
consecutive cases of suspected sporadic CJD were scanned and
the diagnostic sensitivity ranged from 58% to 71% and speciﬁcity
from 82% to 89%, depending on the observer (Tschampa et al.,
2005).
Proton magnetic resonance spectroscopy (
1H-MRS) allows for
the non-invasive and spatially resolved measurement of several
brain compounds including N-acetyl-aspartate (NAA), a neuronal
marker (Kantarci et al., 2008), and myo-inositol (mI) a glial marker
(Brand et al., 1993). The use of
1H-MRS in the investigation of
sporadic CJD patients has been extremely limited. The study of
individual cases has revealed reduced NAA in different brain areas
including basal ganglia/thalamus (Bruhn et al., 1991; Pandya
et al., 2003; Lim et al., 2004) and cortex (Bruhn et al., 1991;
Graham et al., 1993; Lim et al., 2004). When short echo times
were used, myo-inositol was quantiﬁed and found to be markedly
increased (Bruhn et al., 1991). Similar changes have been reported
in the basal ganglia/thalamus of patients with familial CJD
(Waldman et al., 2006; Haik et al., 2008) and variant CJD
(Cordery et al., 2006).
In the present study, we compared the usefulness of magnetic
resonance techniques such as FLAIR-T2, DWI and
1H-MRS in the
differential diagnosis of patients with rapidly progressive neuro-
logical signs compatible with the clinical diagnosis of sporadic
prion disease (Zerr et al., 2000). Given the phenotypic and patho-
logical heterogeneity of sporadic prion diseases, mainly related to
codon 129 polymorphism and prion protein type, the neurochem-
ical proﬁle was obtained by
1H-MRS in four different brain areas,
i.e. thalamus, striatum, cerebellum and occipital cortex, known to
be most commonly affected in the different forms of sporadic
prion disease (Parchi et al., 1999).
Methods
Study design
Patients were enrolled on the basis of clinical and electroencephalo-
graphic features (Steinhoff et al., 2004) (Fig. 1, Table 1). The clinical
criteria of inclusion were based on modiﬁed WHO 1998 criteria
(Zeidler et al., 1998) allowing for a single cognitive deﬁcit, rapidly
progressive cerebellar dysfunction in the absence of cognitive deﬁcits
and illness duration up to 36 months; features which have been shown
to recur consistently among some sporadic human prion disease
subtypes (Parchi et al., 1999). The patients who exhibited a rapidly
progressive dementia, a single cognitive deﬁcit or a rapidly progressive
cerebellar dysfunction and two of the following: myoclonus, visual and
cerebellar symptoms or both, pyramidal and extrapyramidal signs or
both, or akinetic mutism were classiﬁed as probable prion disease in
the presence of periodic sharp and slow wave complexes on EEG, and
as possible prion disease if EEG was negative for periodic sharp and
slow wave complexes. Results of 14-3-3 determination in CSF were
not used for the initial diagnosis.
Subjects
Twenty-nine consecutive patients were recruited from June 2003 to
December 2007 through the Department of Clinical Neurosciences of
the University of Bologna and its related Neurology Services. Ten
healthy volunteers (ﬁve males and ﬁve females) with ages ranging
from 34 to 82 years (6212 years, meanSD) were also studied.
All magnetic resonance scans were performed at the ‘MR
Spectroscopy Unit’ of the Policlinico S. Orsola-Malpighi University
Hospital in Bologna. For all recruited patients, CSF samples were
analysed for the presence of 14-3-3 protein, and a genetic study of
the human prion protein gene was carried out. A post-mortem
examination was performed in 10 patients.
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Hospital Ethics Committee, and written informed consent was
obtained from each participant or relative, in accordance with the
Declaration of Helsinki.
Magnetic resonance imaging and
spectroscopy
Magnetic resonance studies were performed using a 1.5T GE Signa
Horizon LX system equipped with a birdcage head radio-frequency coil
for signal reception and an EchoSpeed gradient system providing a
maximum gradient strength of 22mT/m and maximum slew rate of
120mT/m/ms.
In all recruited patients, axial T1-weighted spin-echo (repetition
time, TR=500ms; echo time, TE=10ms) and FLAIR (TR=8000ms,
inversion time, TI=2000ms, TE=93.5ms) images were acquired
with 5mm thick slices and 1mm inter-slice gap. DWI with the
same slice spacing were obtained using a single-shot spin-echo
planar imaging technique (=90 , TR=10s, TE=100ms).
Gradient strengths were chosen corresponding to a b-factor value
of 900s/mm
2.
In order to carefully localize
1H-MRS regions of interest, contiguous
3mm thick images were also acquired, using axial fast gradient-echo
(TR=250ms; TE=2.5ms). Given the clinical and pathological hetero-
geneity of CJD, regions of interests were selected in brain areas known
to be most frequently involved in the different forms of CJD (Parchi
et al., 1999). Proton magnetic resonance spectra were acquired using
the point resolved spectroscopy single voxel localization sequence
(TE=35ms; TR=4000ms) with chemical shift selective imaging
sequence water suppression. Four voxels were selected (Fig. 2),
to include the bilateral dorso-medial thalamic nuclei (volume
4.0–5.0cm
3; 128 acquisitions), the left striatum (caudate head and
anterior left putamen, volume 2.7–5.0cm
3; 128 acquisitions),
mid-brain occipital cortex (volume 17.8–18.1cm
3; 32 acquisitions)
and left cerebellum (volume 6.0–7.2cm
3; 64 acquisitions). Peak
integrals for NAA, creatine-phosphocreatine (Cr), choline-containing
compounds (Cho) and myo-inositol were calculated using the opera-
tor-independent ﬁtting program LCModel with standard basis sets
(Provencher, 1993). Peak integral values were expressed relative to
Cr and, for NAA, to myo-inositol. The exclusion criterion for metabo-
lite evaluation was an LCModel estimated ﬁtting error 420%, this
being a reliable indicator of poor quality spectra.
Western blot analysis of 14-3-3 protein
The 14-3-3 protein analysis was performed according to Castellani
et al. (2004) with minor modiﬁcations. Brieﬂy, 20ml of CSF was
added to 20mlo f2  sample buffer and boiled for 10min. Following
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE)
on 12% Tris–glycine Mini gels (Bio-Rad), protein was transferred to
Immobilon P transfer membrane (Millipore). Membranes were then
incubated with polyclonal anti-rabbit antibody to the b-isoform of
14-3-3 protein (Santa Cruz), followed by secondary antibody
(donkey anti-rabbit IgG conjugated with horse radish peroxidase,
Amersham), and developed using the ECL plus detection system
(Amersham).
Screening of the prion protein gene,
PRNP
The entire PRNP open reading frame was analysed by PRNP sequen-
cing to determine the codon 129 genotype and the possible presence
of mutations according to Parchi et al. (1999).
Neuropathologic post-mortem studies
The diagnoses of prion disease, including the speciﬁc subtype
according to Parchi et al. (1999), were deﬁnitely established in the
autopsied subjects by western blot analyses of PrP
Sc type from brain
samples and by neuropathologic examination.
Evaluation of diagnostic tests
EEG was considered positive in the presence of periodic sharp and
slow wave complexes (Steinhoff et al., 2004). The CSF 14-3-3 immu-
noassays were performed using western blot, with conformity of
testing methods and interpretation of results conﬁrmed by a blinded
sample exchange programme. All samples were run in duplicate along
with the following controls: positive (detectable 14-3-3 protein from
conﬁrmed CJD subjects), negative (undetectable 14-3-3 protein from
conﬁrmed non-CJD subjects) and ambiguous (from non-CJD subjects
who had trace levels of 14-3-3 protein). The 14-3-3 test, evaluated
by one rater (PP) with 45 years experience, was considered positive
only when the 14-3-3 immunoreactivity was clearly stronger than
that of the ambiguous sample. MRI brain scans were reviewed by
one rater (RL), with a neuroradiological experience of 410 years,
blind to the condition of the patients. The FLAIR and DWI
were scored separately, for the presence or absence of bilateral
Enrolled
(n=2 9 )
INITIAL DIAGNOSIS 
Probable prion 
disease (n=6 )
Possible prion 
disease (n=2 3 )
Clinical and EEG findings
INCLUSION CRITERIA
Died
(n= 14)
Alive
(n=1 5 )
Pathology/
PrP
Sctype (n= 10)
No autopsy
(n= 4)
Definite CJD (n=9 )
Definite sFI (n=1 )
Definite FFI (n=1 )
Probable CJD (n=2 )
Not prion disease (n=1 2 )
Probable CJD (n=1 )
Not prion disease (n=3 )
STUDY PROTOCOL
1H MRS
Thalamus, Cerebellum and 
Occipital cortex (n=2 9 )
Striatum (n=2 2 )
CSF 14-3-3
(n= 29)
FLAIR-T2 (n=2 9 )
DWI (n=2 9 )
PRNP gene 
screening 
(n= 28)
Definite CJD (n=9 )
Definite sFI (n=1 )
Definite FFI (n=1 )
Probable CJD (n=3 )
FINAL DIAGNOSIS 
Not prion disease (n=1 5 )
Figure 1 Summary of subject enrolment and study design.
sFI=sporadic fatal insomnia; FFI=familial fatal insomnia.
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2672 | Brain 2009: 132; 2669–2679 R. Lodi et al.increased signal intensity (SI) in the striatum, thalamus and cerebral
cortex. High signal in the striatum and/or in the cerebral cortex were
considered a positive ﬁnding (Collie et al., 2001; Tschampa et al.,
2007).
Statistical analysis
Statistical analysis was performed with Statistical Package for Social
Science Software (SPSS, version 13.0, Chicago, IL) for Windows.
One-way analysis of variance (ANOVA) was performed for com-
parison of
1H-MRS metabolite ratios and concentrations between the
subject groups. The statistical comparison of spectroscopic values was
performed using parametric tests, since a Kolmogorov–Smirnov ana-
lysis showed that all the variables were normally distributed (data not
shown). The threshold of signiﬁcance was set at P50.05. When it
was determined that differences existed among the groups, Student’s
t-tests were performed to determine which mean values differed,
using the Bonferroni correction for multiple comparisons. For each
numerical MR spectroscopic variable, the optimal cutoff values, that
gave the best balance between sensitivity and speciﬁcity, were
determined by receiver operating characteristic curve analysis
(Armitage et al., 2002). Sensitivity, speciﬁcity, positive predictive
value (PPV), negative predictive value (NPV) and the number of
cases correctly identiﬁed were calculated to determine the diagnostic
capability of
1H-MRS variables, DWI and CSF 14-3-3 protein.
Univariate logistic regression analysis, employing a backward stepwise
inclusion method, was developed using a P-value of 0.05 to discriminate
which variables affected the outcome. The regression coefﬁcients and
standard errors (SE) of the independent variables were calculated. Those
coefﬁcients not signiﬁcantly different from zero were removed from the
regression model. Finally, odds ratios (OR) and conﬁdence intervals (CI)
of variables included in the models were calculated, and a classiﬁca-
tion table was used to evaluate the predictive accuracy of the model.
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Figure 2 Proton magnetic resonance spectra localization: (A)
bilateral dorso-medial thalamus, (B) left striatum (caudate head
and anterior putamen), (C) left cerebellum and (D) mid brain
occipital cortex.
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Clinical, electroencephalography and
cerebrospinal ﬂuid ﬁndings
Among the 29 patients recruited, on the basis of clinical and EEG
features, 6 had an initial diagnosis of probable and 23 of possible
prion disease.
A deﬁnite diagnosis of either CJD or fatal insomnia was made in
10 patients (Table 1). Among these patients, nine had a ﬁnal
diagnosis of deﬁnite CJD (three VV2, three MV2 and three
MM1 patients) (Zerr et al., 2000) and one of sporadic fatal
insomnia (MM2). Case #3 (MM1) and Case #7 (MV2) turned
out to be genetic CJD cases, despite the lack of family history
and apparent sporadic occurrence at clinical examination. Case
#14 carried the D178N mutation and therefore was diagnosed
as deﬁnite familial fatal insomnia even without post-mortem
examination. In three patients (two still alive, Cases #11 and
#12, and one dead without post-mortem examination, Case #5),
all positive for 14-3-3 protein, the ﬁnal diagnosis was, according
to Zerr et al. (2000), probable CJD. As detailed in Table 1, the
clinical follow-up excluded the diagnosis of prion disease in the
remaining 15 patients who, in most cases, were affected by other
neurodegenerative or inﬂammatory disorders. Two patients with
probable (Case #28) and possible (Case #29) prion disease had a
much shorter follow-up, but the diagnosis of prion disease could
be excluded on the basis of a substantial clinical improvement
from onset. All the non-prion patients, except Case #24 who
was not tested, were negative for PRNP mutations.
EEG was positive for periodic sharp and slow wave complexes in
4/14 patients with prion disease and 2/15 patients without prion
disease.
The 14-3-3 protein test in CSF was judged positive in 12/14
prion patients and in 2/15 non-prion patients. Among prion-
affected subjects, the 14-3-3 protein test was negative in the
two patients affected by the sporadic (Case #2) or familial (Case
#14) subtype of fatal insomnia. Among non-prion patients, Cases
#28 and #29 were false positive.
Magnetic resonance imaging and
spectroscopy
The comparison of FLAIR-T2 and DWI SI changes in the striatum,
thalamus and cerebral cortex for the 29 patients is reported in
Table 2, and some example images demonstrating characteristic
features are shown in Fig. 3. DWI clearly demonstrated a
much higher sensitivity than FLAIR-T2 images in detecting SI
increase in the thalamus and cerebral cortex. Among prion
patients, DWI showed increased SI in the striatum of 12 cases,
in the thalamus of 6 cases and in the cerebral cortex of 8 cases.
Subjects #2 and #14, with sporadic and familial fatal insomnia,
were the only false negative prion cases. Two patients without
prion disease showed high SI in the striatum and thalamus (Case
#18) and cerebral cortex (Case #28) on both FLAIR-T2 and DWI.
All the other non-prion patients showed normal SI in the deep
grey matter and cerebral cortex on both sequences.
Single voxel
1H-MRS was performed in four regions of interest:
thalamus, cerebellum, striatum and occipital cortex (Fig. 2). The
mean line width of the water resonance of the subjects included in
the study was 6.771.99 (SD) Hz in the striatum compared with
3.950.99 in the thalamus, 4.250.90 in the cerebellum and
3.620.58 in the occipital cortex. The higher widths in the
striatum resulted in the exclusion (estimated ﬁtting error 420%)
of spectra from the striatum of four prion patients, three non-
prion patients and two controls. myo-inositol to Cr ratios from
the striatum, cerebellum and occipital cortex of one non-prion
patient and from the striatum of one control were also excluded
from the analysis due to an estimated ﬁtting error 420% for
myo-inositol.
The most signiﬁcant neuro-metabolic group differences were
detected in the thalamus and cerebellum (Table 3). In the thala-
mus of prion patients, post hoc testing (Fig. 3 and Table 4)
revealed a reduction in NAA/Cr and NAA/myo-inositol, and an
elevation of myo-inositol/Cr, compared with both non-prion and
Table 2 Evaluation of SI in FLAIR-T2 and DWI images
of patients with or without prion disease
Case FLAIR-T2 DWI
# Striatum Thalamus Cerebral
cortex
Striatum Thalamus Cerebral
cortex
Patients with prion disease
1+  ++ 
2   
3+  +  +
4+ +  ++ 
5 ++ +++ +
6+  ++ +
7+  ++ 
8+  +++ +
9  +  +
10 +  ++ 
11 +  ++ +
12 +  ++ +
13 +  +  +
14   
Patients without prion disease
15   
16   
17   
18 + +  ++ 
19   
20   
21   
22   
23   
24   
25   
26   
27   
28  +  +
29   
SI was evaluated in the striatum, thalamus and cerebral cortex.
+=hyperintensity; =normal SI.
2674 | Brain 2009: 132; 2669–2679 R. Lodi et al.control subjects. Non-prion patients, compared with controls,
showed a lower thalamic NAA/Cr. In the two groups of patients,
NAA/Cr in the striatum were similarly reduced compared with
controls. In the cerebellum of prion patients, NAA/Cr and NAA/
myo-inositol were reduced compared with controls.
Differential diagnosis between patients
with and without prion disease
The initial diagnosis, based on clinical and EEG ﬁndings, of prob-
able prion disease showed a sensitivity of 29% and a speciﬁcity of
87%. Seventy-one percent of prion patients and 87% of the
patients without prion disease were initially diagnosed as possible
prion disease. The 14-3-3 protein test in CSF showed a diagnostic
sensitivity, speciﬁcity, NPV and PPV of 86, 87, 86 and 87%,
respectively, with the number of cases correctly diagnosed equal
to 86% (Table 5).
Considering the receiver operating characteristic curve analysis
(Table 5), thalamic
1H-MRS variables showed the greatest ability
to differentiate between patients with and without prion disease.
In particular, NAA/Cr showed a 100% sensitivity and 100% NPV,
and NAA/myo-inositol a 100% speciﬁcity and 100% PPV in
differentiating prion from non-prion patients. Cerebellar
1H-MRS
variables showed, compared with thalamic
1H-MRS, a much lower
differential diagnostic power (Table 5).
Diffusion-weighted imaging showed a diagnostic sensitivity,
speciﬁcity, NPV and PPV of 86, 87, 86 and 87%, respectively;
identical to that found for the 14-3-3 protein (Table 5).
The percentages of correct diagnoses were comparable for
thalamic NAA/Cr (86%), thalamic NAA/myo-inositol (90%) and
diffusion-weighted imaging (86%) and for CSF 14-3-3 protein
(86%). The two false negative prion cases on diffusion-weighted
imaging (Cases #2 and #14) were correctly diagnosed using tha-
lamic NAA/Cr and NAA/myo-inositol, and the four false positive
non-prion patients based on thalamic NAA/Cr values (Cases #19,
#24, #27 and #28) were correctly diagnosed as non-prion by
diffusion-weighted imaging (#19, #24 and #27) and/or thalamic
NAA/myo-inositol (Cases #19, #24, #27 and #28). When the
three patients classiﬁed as prion patients without a post-mortem
or genetic conﬁrmation of the diagnosis (Cases #5, #11 and #12,
Table 1) were excluded from the analysis, the percentages of
correct diagnoses was similar: thalamic NAA/Cr (85%), thalamic
NAA/myo-inositol (90%), and diffusion-weighted imaging (85%)
and for CSF 14-3-3 protein (85%).
Figure 3 FLAIR-T2 (top) and DWI (middle), and thalamic
1H-MRS (bottom) from Case #4 with deﬁnite sporadic CJD, VV2 (A), Case
#2 with deﬁnite sporadic fatal insomnia, MM2 (B), Case #18 with possible autoimmune encephalitis (C) and Case #6 with deﬁnite
sporadic CJD, MM1 (D). On MRI, Case #4 shows increased SI in the striatum and thalamus, Case #2 no SI changes, Case #18
increased SI in the striatum and thalamus and Case #6 increased SI in the striatum and cerebral cortex. On
1H-MRS of the thalamus,
all the three prion patients (A, B and D) showed, relative to creatine-phosphocreatine (Cr) a severe reduction of the neuronal marker
NAA. The patient without prion disease (C) showed normal thalamic spectrum. ppm=parts per million.
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NAA/myo-inositol, diffusion-weighted imaging, CSF 14-3-3 protein
and EEG results showed that the only variables relevant to the diag-
nostic outcome were either thalamic NAA/Cr (P=0.033, OR=0.00,
95% CI 0.00–0.25, regression coefﬁcientSEM=17.728.33)
and diffusion-weighted imaging (P=0.038, OR=66.09, 95% CI
1.27–3436.26, regression coefﬁcientSEM=4.192.02) or
thalamic NAA/Cr (P=0.034, OR=0.00, 95% CI 0.00–0.27, regres-
sion coefﬁcientSEM=–17.748.38) and CSF 14-3-3 protein
(P=0.038, OR=63.80, 95% CI 1.24–3262.15, regression
coefﬁcientSEM=4.152.01). The combination of thalamic
NAA/Cr and diffusion-weighted imaging or thalamic NAA/Cr and
CSF 14-3-3 protein showed the same predictive accuracy (93%)
in classifying patients as prion or non-prion.
Table 3
1H-MRS data obtained in four different regions of interest from patients with prion disease, patients without
prion disease and healthy controls
Regions of interest NAA/Cr Cho/Cr mi/Cr NAA/mi
Thalamus
Patients with prion disease (14) 0.980.13 0.300.07 1.050.19 0.960.21
Patients without prion disease (15) 1.240.11 0.310.05 0.860.23 1.640.84
Healthy subjects (10) 1.370.12 0.310.04 0.820.15 1.710.25
P (ANOVA) 50.001 0.939 0.014 0.002
Striatum
Patients with prion disease (10) 0.850.16 0.280.04 0.860.29 0.970.33
Patients without prion disease (12) 0.870.17 0.270.05 0.890.39
1 1.270.80
1
Healthy subjects (8) 1.090.24 0.240.07 0.730.08
2 1.550.32
2
P (ANOVA) 0.021 0.431 0.567 0.152
Cerebellum
Patients with prion disease (14) 0.850.22 0.250.04 0.720.14 1.230.38
Patients without prion disease (15) 0.990.10 0.270.06 0.650.13
3 1.580.36
3
Healthy subjects (10) 1.150.16 0.270.04 0.650.12 1.710.31
P (ANOVA) 0.001 0.411 0.283 0.014
Occipital cortex
Patients with prion disease (14) 1.190.16 0.170.03 0.820.16 1.510.42
Patients without prion disease (15) 1.260.14 0.190.03 0.720.14
3 1.890.92
3
Healthy subjects (10) 1.320.07 0.190.02 0.780.11 1.710.21
P (ANOVA) 0.071 0.218 0.187 0.298
Data are expressed as meanSD. ANOVA test: P50.05 were considered signiﬁcant. The number of spectra included in the analysis is indicated in parenthesis. When
individual metabolites were not included in the analysis (SD 420%) superscript numbers are used:
1n=11;
2n=7;
3n=14; mi=myo-inositol.
Signiﬁcant P values are indicated in bold.
Table 5 Sensitivity, speciﬁcity, predictive values and
percentage of cases correctly diagnosed of
1H-MRS
variables from the thalamus and cerebellum, DWI and CSF
14-3-3 protein for the discrimination between patients
with and without prion disease
1H-MRS—thalamus (cutoff) NAA/Cr 41.21 NAA/mi 41.05
Sensitivity (%) 100 79
Speciﬁcity (%) 73 100
PPV (%) 78 100
NPV (%) 100 83
Cases correctly identiﬁed (%) 86 90
1H-MRS—cerebellum (cutoff) NAA/Cr 40.88 NAA/mi 41.53
Sensitivity (%) 64 86
Speciﬁcity (%) 87 57
PPV (%) 82 67
NPV (%) 72 80
Cases correctly identiﬁed (%) 76 62
DWI CSF 14-3-3
Sensitivity (%) 86 86
Speciﬁcity (%) 87 87
PPV (%) 86 86
NPV (%) 87 87
Cases correctly identiﬁed (%) 86 86
For
1H-MRS variables cutoff values were determined by receiver operating
characteristic curve analysis; mi=myo-inositol.
Table 4 Post hoc analysis of
1H-MRS variables that were
signiﬁcant on the ANOVA test (Table 3)
Prion patients
versus
non-prion
patients
Prion patients
versus
healthy
subjects
Non-prion patients
versus healthy
subjects
Thalamus
NAA/Cr 50.001 50.001 0.038
mi/Cr 0.045 0.028 NS
NAA/mi 0.006 0.007 NS
Striatum
NAA/Cr NS 0.034 0.048
Cerebellum
NAA/Cr NS 50.001 NS
NAA/mi NS 0.035 NS
The Student’s t-test after Bonferroni correction for multiple comparisons was
used, applying a signiﬁcance threshold of P50.05; mi=myo-inositol; NS=not
signiﬁcant.
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In this study, we evaluated the accuracy of different magnetic
resonance modalities such as
1H-MRS, diffusion-weighted imaging
and FLAIR-T2, in the diagnosis of prion disease. Based on modiﬁed
clinical and EEG WHO-1998 criteria (Zeidler et al., 1998), all
patients included had an initial diagnosis of possible or probable
prion disease. Clinical follow-up, genetic studies and, when avail-
able, post-mortem examination were used to classify patients as
prion or non-prion. Fourteen out of 29 patients were diagnosed
with prion disease. The percentage of correctly diagnosed cases
was 86% for diffusion-weighted imaging (hyperintensity in the
striatum and/or cerebral cortex), 86% for thalamic NAA/creatine
(cutoff 41.21), 90% for thalamic NAA/myo-inositol (cutoff
41.05) and 86% for CSF 14-3-3 protein. All of the prion disease
patients had NAA/Cr ratios 41.21 (100% sensitivity and 100%
NPV), while all the non-prion patients had NAA/myo-inositol
ratios above 1.05 (100% speciﬁcity and 100% PPV). Non-linear
discriminant analysis showed that the combination of thalamic
NAA/Cr and diffusion-weighted imaging was best for correctly
classifying patients as prion or non-prion (accuracy 93%).
The present study systematically evaluated, for the ﬁrst time,
the diagnostic value of
1H-MRS in the differential diagnosis of
prion disease by assessing the metabolite content in brain regions
such as the thalamus, striatum, cerebellum and occipital cortex
known to be affected in most subtypes of sporadic prion disease
(Parchi et al., 1999). Previous
1H-MRS studies on small numbers
of patients with classic or variant CJD have detected a variable
distribution of neuro-metabolic changes. In general, reduced NAA
content and/or increased myo-inositol were detected, in compar-
ison with healthy subjects, in the basal ganglia, thalamus and
cerebral cortex (Bruhn et al., 1991; Graham et al., 1993;
Pandya et al., 2003; Lim et al., 2004; Cordery et al., 2006;
Fulbright et al., 2006; Waldman et al., 2006).
The most striking neuro-metabolic differences between prion
patients and healthy controls, found by our study, were in the
thalamus and cerebellum, where metabolite ratios NAA/Cr and
NAA/myo-inositol showed a marked reduction compared with
healthy subjects: 28 and 44% in the thalamus and 26 and
28% in the cerebellum, respectively. These
1H-MRS changes
reﬂect two main neuropathological features of prion disease: neu-
ronal loss, responsible for the reduction of the neuronal marker
NAA (Kantarci et al., 2008) and glial activation, responsible for the
increase in the glial marker myo-inositol (Brand et al., 1993). The
less severe
1H-MRS changes detected in prion cases compared
with healthy controls in the striatum and cerebral cortex probably
have two different explanations. Spectroscopic magnetic reso-
nance measurements in the striatum are particularly challenging
due to susceptibility effects that resulted in an increased peak line
width and reduced the precision of peak quantiﬁcation. On the
other hand, the involvement of cerebral cortex in prion disease is
strictly related to the disease subtype (Parchi et al., 1999).
In particular, cortical involvement was absent at the time of the
MR scan in VV2, MV2 and fatal insomnia (see Cases #1, #2, #4,
#7, #10 and #14), which is consistent with previous ﬁndings
(Tschampa et al., 2007).
The most signiﬁcant neuro-metabolic differences between prion
and non-prion patients were found in the thalamus. In prion
compared with non-prion patients, thalamic NAA/Cr was reduced
by 21% and NAA/myo-inositol by 41%. Myo-inositol/Cr in prion
cases was increased by 22%. Non-prion patients showed,
compared with healthy controls, a reduction in NAA/Cr in the
thalamus, much milder than that detected in prion patients, but
a reduction to a similar degree to the prion cases in the striatum.
In addition, non-prion patients showed normal NAA/myo-inositol
in the thalamus.
All our suspected prion patients underwent a neuroimaging
study that included axial FLAIR-T2 and DWI sequences. In prion
patients, these sequences have been reported to be the most
sensitive in the detection of the diagnostic increase in SI in the
basal ganglia and/or cortex (Collie et al., 2001; Shiga et al., 2004;
Tschampa et al., 2005; Kallenberg et al., 2006; Macfarlane et al.,
2007). Diffusion-weighted imaging showed increased SI in the
striatum and/or in the cortex of all prion patients except
Cases #2 and #14. Increased SI on DWI was present in the
striatum in 86% of cases whereas increased cortical SI was
detected in 57%. FLAIR images showed a SI increase in the
striatum in 79% of the prion patients and in the cortex in only
42%, conﬁrming the higher sensitivity of DWI compared with
FLAIR in detecting increased SI in prion disease. Hyperintense
regions in DWI images are characterized by reduced values of
the water apparent diffusion coefﬁcient (Bahn and Parchi, 1999;
Tschampa et al., 2003; Manners et al., 2009). A combined effect
of T2 and apparent water coefﬁcient changes are likely to be
responsible for the more striking abnormalities seen on DWI
compared with FLAIR sequences.
The only DWI false negative Cases (#2 and #14) were sporadic
or genetic fatal insomnia cases. These prion disease subtypes are
characterized by lack of spongiform changes in the basal ganglia
and thalamus and by only late and small cortical spongiform
changes (Parchi et al., 1999). It has recently been demonstrated
that spongiform changes are the pathological basis underlying
increased SI (Manners et al., 2009). Indeed, this was also the
case for our sporadic fatal insomnia patient (Case #2) where
pathology revealed a severe neuronal loss and gliosis in the tha-
lamus in the absence of signiﬁcant spongiosis (P. Parchi, personal
communication). The absence of increased SI on DWI, associated
with the lack of spongiform changes, has previously been reported
in one case of sporadic fatal insomnia (Shiga et al., 2004) and in
patients with familial fatal insomnia (Montagna et al., 2003; Haik
et al., 2008). In both cases of fatal insomnia, thalamic
1H-MRS
showed a severe reduction in NAA/Cr conﬁrming the early and
severe neuronal loss, and, in the patient with sporadic fatal
insomnia. an increase in myo-inositol/Cr indicating glial prolifera-
tion 11 months before death. These ﬁndings are consistent with a
recent combined
1H-MRS and pathological study of a patient with
familial fatal insomnia where marked thalamic in vivo increase in
myo-inositol content was associated with severe gliosis at post-
mortem (Haik et al., 2008).
The largest available MRI studies of CJD patients are retrospec-
tive, and used mainly T2- and proton density-weighted images to
evaluate SI in the caudate nucleus and putamen (Tschampa et al.,
2005; Collins et al., 2006). Tschampa and colleagues studied 193
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ranging from 58.3% to 70.8%, depending on the rater, and a
speciﬁcity 480%. A much lower diagnostic sensitivity was
reported by Collins and colleagues in a larger multi-centre study
that found the typical striatial hyperintensity in only 39.1% of
1036 deﬁnite CJD patients. The low utilization of more recent
and sensitive pulse sequences, such as FLAIR and DWI, and the
lack of evaluation of cerebral cortical signal are the most likely
explanations of the much lower sensitivity and speciﬁcity
demonstrated in these large studies compared with ours and
other smaller, more recent MRI studies utilizing FLAIR-T2 and
DWI sequences, which all showed a sensitivity and speciﬁcity
90% (Shiga et al., 2004; Young et al., 2005).
Several of our prion patients presented an increased SI in the
thalamus on DWI (43%). All of our patients with increased SI in
the thalamus also showed high SI in the striatum. Previous DWI
studies have shown a lower detection of increased SI in the
thalamus of CJD patients (Shiga et al., 2004; Young et al.,
2005; Kallenberg et al., 2006) ranging from 12.5% (3 out of
26, Shiga et al., 2004) to 34% (14 out of 40, Young et al.,
2005). The higher percentage of thalamic abnormalities in our
study may be related to the presence, in our CJD group, of a
prevalence of VV2 and MV2 subtypes, both characterized by a
severe pathological thalamic involvement (Parchi et al., 1999) and
high frequency of increased SI on DWI/T2-weighted images
(Krasnianski et al., 2006; Heinemann et al., 2007). Indeed all
our CJD patients with high thalamic SI were VV2 or MV2
subtypes. As previously reported, none of our MM1 patients
showed increased thalamic SI (Krasnianski et al., 2006;
Heinemann et al., 2007).
Only two non-prion patients presented increased SI on FLAIR
and DWI in the striatum and thalamus (Case #18) and cerebral
cortex (Case #28). Case #18, who presented normal thalamic
NAA/Cr and NAA/myo-inositol, was affected by encephalitis
that was probably due to autoimmunity against deep grey
matter neurons (Dale et al., 2004). In this patient corticosteroid
therapy resulted in a regression of symptoms and signs and a
resolution of SI enhancement in both FLAIR and DWI. Case #28
presented with subentrant epileptic seizures at the time of the
scan, probably causing the increase in cortical SI. In this patient,
CSF 14-3-3 protein was high at the time of the scan but normal-
ized 4 months later, in association with a clinical improvement.
The diagnostic capability of combined DWI and thalamic
1H-MRS to correctly identify prion and non-prion patients was
slightly higher than the increase in the 14-3-3 protein in the
CSF. Using 14-3-3 protein levels, 86% of patients were correctly
classiﬁed in our study, in line with previous reports (Collins et al.,
2006; Sanchez-Juan et al., 2006). On the other hand, the contri-
bution of EEG to the correct diagnostic classiﬁcation of our
patients was poor compared with other studies, with a sensitivity
530%. This may be due to the prevalence in our study of
CJD subtypes (VV2, MV2, thalamic MM2 and familial fatal insom-
nia) characterized by a relatively mild and late cortical involvement
(Parchi et al., 1999).
In conclusion, we combined conventional MRI and
1H-MRS in
the differential diagnosis of patients with possible or probable
prion disease on the basis of clinical features. Thalamic
1H-MRS
(NAA/Cr and NAA/myo-inositol) and DWI showed a very high
correct diagnostic classiﬁcation (86–90%). Most importantly, (i)
the combination of
1H-MRS and DWI results could predict prion
disease (=PPV) in a patient positive for both increased SI on DWI
and reduced thalamic NAA/Cr on
1H-MRS with a likelihood of
100%; (ii) the likelihood of not having a prion disease (=NPV)
in a patient with the absence of both SI increase on DWI and
NAA/myo-inositol reduction on thalamic
1H-MRS was equal to
100% and (iii) the combination of thalamic NAA/Cr and DWI in
a logistic regression analysis resulted in a correct classiﬁcation of
93% of patients.
This study was performed on a relatively small number of
patients. However, it was a prospective study in which, unlike
most of the previous studies, the non-prion patients were all
recruited on the basis of a clinical presentation of ‘possible’ or
‘probable’ prion disease. This allowed a more correct evaluation
of the speciﬁcity of the diagnostic magnetic resonance markers.
Although further work on a larger and more varied patient
population will be needed, overall our ﬁndings indicate that the
combination of thalamic
1H-MRS (acquisition duration 10min) and
brain DWI (acquisition duration 2min) may increase the diagnostic
accuracy of the magnetic resonance scan and that both sequences
should be included routinely in the clinical work-up of patients
with suspected prion disease.
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